Synopsis

Uncertainty in the quantification of imaging biomarkers from MRI can be minimized by the control of different aspects of the quantification process, based on the principles of metrology science. Both technical and clinical validation are fundamental for the success of the biomarker. Technical validation includes the determination of the accuracy and precision of the measurement. Nevertheless, a biomarker can be not properly adopted in clinical routine if it is not clinically validated. For that, the inclusion of clinical endpoints such as the ones handled in oncology (overall survival, event free survival) is fundamental to demonstrate utility of quantitative imaging.